RB1 and malignant glioma: Additionally, in high-grade malignant gliomas, several molecular genetic studies have established mutations in diverse pathways promoting oncogenic capacity, such as RTK-PI3K-PTEN and ARF-MDM2-p53 INK4a-RB [43].